PTC Eyes Transition From Capital-Raising To Money-Making Company

 
• By Mandy Jackson

With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.

Businessman accountant counting money and making notes at report doing finances and calculate about cost of investment and analyzing financial data, Financing Accounting Banking Concept.
PTC may be profitable by 2023 based on product sales and royalties • Source: Shutterstock

More from Strategy

More from Business